Navigation Links
A New Lambda Vector for Mammalian Expression


The Lambda ZAP-CMV vector for efficient library construction and mammalian expression

Quinn Lu Tanya Hosfield Cherie Dewar Tim Sanchez Mike Kobrin
Stratagene

Stratagenes new lambda cloning vector, the Lambda ZAP -CMV vector,* contains the left and right arms of the Lambda ZAP II vector and the pCMV-Script -EX phagemid vector. High-efficiency cDNA libraries constructed in the Lambda ZAP-CMV vector can be converted to plasmid libraries by a simple in vivo excision procedure. This vector preserves the benefits of lambda library construction, while providing the convenience of plasmids for expression in mammalian cells and characterization of cloned inserts.

Stratagenes family of Lambda ZAP vectors is designed to simplify the construction of high-titer cDNA libraries and the characterization of inserted DNA. These vectors are distinguished by their capability to easily excise and recircularize cloned insert DNA from lambda phage. When either single clones or the entire lambda library is converted to a plasmid format by in vivo excision,1-5 they combine the high-efficiency cloning of lambda vectors with the convenience of plasmid libraries for functional studies. This elegant procedure requires very little hands-on time and eliminates the need for subcloning procedures.

High-Level Expression in Mammalian Cells

Figure 1

Stratagenes new lambda vector, the Lambda ZAP-CMV vector, offers efficient library construction and, upon mass excision, high-level eukaryotic expression in the pCMV-Script-EX phagemid vector. The Lambda ZAP-CMV vector (Figure 1) contains lambda arms derived from the Lambda ZAP II vector, three unique restriction sites in the multiple cloning site, and the pCMV-Script-EX phagemid vector.

Figure 2

The pCMV-Script-EX vector contains 15 unique sites for cloning (Figure 2) and offers the same features as its parental pCMV-Script vector;6 gene expression driven by the CMV promoter for constitutive expression in a wide variety of cell lines;### the SV40 polyadenylation site; and the neomycin-resistance gene under control of the prokaryotic b-lactamase promoter, to provide kanamycin resistance in bacteria, as well as the SV40 early promoter, to provide G418 resistance in mammalian cells. The pCMV-Script-EX vector varies from its parental pCMV-Script vector by a 29-bp sequence downstream of the f1 origin; however, this additional sequence is in a nonfunctional region of the vector. Thus, the new pCMV-Script-EX vector is functionally equivalent to the pCMV-Script vector.

The Lambda-ZAP CMV vector is available in kits of varying components to accommodate different research needs. The Lambda ZAP-CMV XR library construction kit includes the directional cDNA synthesis kit, the Lambda ZAP-CMV XR vector, Gigapack III Gold packaging extract, host strains, and helper phage. Lambda ZAP-CMV vector kits are available that include the Lambda ZAP-CMV vector predigested with either EcoR I only or EcoR I and Xho I, host strains, and helper phage. In addition, the Lambda ZAP-CMV vector is available in undigested form with host strains and helper phage.

cDNA Library Construction in the Lambda ZAP-CMV Vector

Figure 3

Libraries constructed in the Lambda ZAP-CMV vector are characterized by high titers and robust plaque size. We constructed a cDNA library in the EcoR I and Xho I sites of the Lambda ZAP-CMV vector using poly(A)+ RNA from human HeLa cells. This library contained approximately 3 x 106 primary plaques. The phage titer of the amplified library was 2 x 1010 plaque-forming units (pfu)/ml. To assess the library quality (background level and insert size), we mass excised and selected phagemid colonies by antibiotic selection on kanamycin plates. Plasmid DNA was prepared from 12 randomly picked colonies, and the DNA was digested with either EcoR I and Xho I or Not I and Kpn I restriction enzymes. All 12 clones contained a cDNA insert, ranging in size from 0.5 kb to 2.5 kb, with an average size of 1.4 kb (Figure 3). The titer of the amplified library in the Lambda ZAP-CMV vector remained constant upon storage at 4C, -80C, and in the presence of 7% DMSO.

Luciferase Expression in the pCMV-Script -EX Vector

Figure 4

To demonstrate expression levels in the pCMV-Script-EX vector, we inserted the firefly luciferase gene into the BamH I site of the MCS. This same luciferase gene was inserted into the parental pCMV-Script vector. These two constructs were used for parallel transfections of Chinese hamster ovary (CHO) cells. Cell lysates were prepared and assayed for luciferase activity. In Figure 4, cells transfected with each construct show comparable luciferase activity. We also detected luciferase protein in both samples by Western blot analysis (data not shown). To further demonstrate the functionality of the pCMV-Script-EX vector, we transfected the pCMV-Script-EX vector with luciferase gene construct into CHO cells and selected cells with G418 to establish a stable transfected cell line with high levels of luciferase expression (data not shown). These data confirm that the pCMV-Script-EX phagemid vector expresses high levels of protein in mammalian cells.

Lambda ZAP Vectors for Diverse Applications

Table 1
Stratagenes Lambda ZAP cDNA Library Vectors

Comparison of Lambda cDNA Library Vectors

HybriZAP 2.1
two-hybrid vector

ZAP Express
vector

Lambda ZAP-CMV
vector

Lambda ZAP II
vector

# unique cloning sites in l
(# sites in excised plasmid)

2
(7 in pAD-GAL4-2.1)

12
(17 in pBK-CMV)

3
(15 in pCMV-Script)

6
(21 in pBluescript SK- phagemid)

cloning capacity

6 kb

12 kb

6.5 kb

10 kb

eukaryotic expression

yes
(pADH1 promoter)

yes
(CMV promoter)

yes
(CMV promoter)

no

prokaryotic blue/white color screening
and b-gal fusion protein expression

no

yes

no

yes

contains excisable phagemid

yes

yes

yes

yes

antibiotic resistance

Ampr

Kanr

Kanr

Ampr

eukaryotic selection

leucine

G418

G418

none

directional cloning

yes

yes

yes

yes

suitable helper phage

VCSM13,
ExAssist helper phage

R408, RE704,
ExAssist helper phage

R408, RE704,
ExAssist helper phage

R408, VCSM13, RE704,
ExAssist helper phage

ssDNA mutagenesis

yes

yes

yes

yes

T3/T7 RNA polymerase promoters

T7 only

yes

yes

yes

exo-mung deletions

no

yes

yes

yes

The Lambda ZAP vectors (Table 1) are available for prokaryotic expression (the Lambda ZAP II vector), two-hybrid screening in yeast (the HybriZAP 2.1 vector), both prokaryotic and eukaryotic expression (the ZAP Express vector), and now, the new Lambda ZAP-CMV vector. The Lambda ZAP II vector is the most widely used vector for constructing cDNA libraries. Libraries cloned in this vector can be functionally screened with nucleic acid probes or antibodies. Alternatively, the library can be quickly and easily mass excised into the pBluescript SK(-) plasmid vector for analysis of transcripts via expressed sequence tag (EST) sequencing or subtraction and normalization procedures. The HybriZAP 2.1 vector offers the convenience of lambda library technology; after library construction, excision of the pAD-GAL4-2.1 plasmid vector allows cloned DNA to be screened for protein-protein interactions in vivo. The ZAP Express vector offers library construction with the capability for both prokaryotic and eukaryotic expression. Libraries constructed in the ZAP Express vector can be easily screened, and individual clones can be quickly converted to the pBK-CMV vector for eukaryotic transcription directed by the cytomegalovirus (CMV) immediate early promoter; this results in mid-level expression of cloned genes in mammalian cells.

Conclusions

Stratagenes Lambda ZAP vectors are designed for simplified construction of high-titer cDNA libraries, combined with the capability for excision and recircularization of cloned insert DNA from lambda phage. With the simple in vivo excision procedure, convert either individual clones or entire lambda libraries to a plasmid format. And, the newest lambda cloning vector, the Lambda ZAP-CMV mammalian expression vector, features the pCMV-Script-EX phagemid to achieve the highest levels of expression in mammalian cells.

Acknowledgments

We thank members of the Research and Development group, the Vector group, and the Custom Library group at Stratagene for discussion and suggestions.

REFERENCES
  1. Short, J.M., et al. (1988) Nucleic Acids Res. 16: 7583-7600.

  2. Alting-Mees, M., et al. (1992) Strategies 5: 58-61.

  3. Alting-Mees, M. and Short, J.M. (1989) Nucleic Acids Res. 17: 9494.

  4. Amberg, J., et al. (1993) Strategies 6: 2-4.

  5. Mullinax, R.L. and Sorge, J.A. (1995) Strategies 8: 3-5.

  6. Hosfield, T., et al. (1997) Strategies 10: 68-69.

* U.S. Patent Nos. 5,128,256 and 5,286,636 and European Patent No. 286200


'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. Highly Active and Removable AffinityTagged Lambda Phosphatase
2. Lambda DNA Extraction Protocol
3. Lambda DNA Extraction Protocol
4. A New C-Terminal GST Vector for Protein Production in S. pombe
5. Generate Adenovirus Vectors in E. coli by Homologous Recombination with the AdEasy Adenoviral Vector System
6. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
7. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
8. Epitope-Tagging Vectors for Functional Analysis in Yeast
9. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
10. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
11. High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Lambda Vector for Mammalian Expression

(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... Enhances ... Senior Management Team, ROCKVILLE, Md., June 18 EntreMed, ... the treatment of cancer and inflammatory diseases, today,announced the appointment ... and Business Development. Mr. Bliss has been elected,an executive officer ...
... Access to data may provide potential for label expansion ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today ... Bayer,s phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT ... be appropriate for CTI to begin discussions with the,U.S. ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... guidance for full year 2008,revenue to be in the ... year,2008 earnings per adjusted pro-forma fully diluted share (excluding ... IPO) to be in the,range of $0.87 to $0.94. ...
Cached Biology Technology:EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Researchers from the Institute of Food Research and The ... a gut bacterium, to help understand how these organisms ... relationship between gut bacteria and the gastrointestinal tract is ... the role of bacteria in establishing and maintaining gut ...
... , Higher temperatures could significantly impact California and other ... next 30 years, according to a new study led ... June 30 edition of Environmental Research Letters , ... land suitable for cultivating premium wine grapes in high-value ...
... BALTIMORE, June 29, 2011 BD Biosciences, a ... today the availability of BD Recharge™, a chemically ... manufacturing that offers productivity comparable to yeast-based peptones. ... significant advance for biopharmaceutical cell culture," said Robert ...
Cached Biology News:Genome analysis will reveal how bacteria in our guts make themselves at home 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
...
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: